Nebenwirkungen · Erbitux
Erbitux 5 mg/mL solution for infusion · Abschnitt 4.8 · PDF-Seite 9
HOS-113171 · Präparat HOS-093871
The safety of cetuximab in combination with encorafenib (300 mg orally once daily) (dosed as per its SmPC) was evaluated in 216 patients with BRAF V600E-mutant metastatic colorectal cancer, based on the phase III study ARRAY-818-302. The most common ADRs (>25%) reported in this population were: fatigue, nausea, diarrhoea, dermatitis acneiform, abdominal pain, arthralgia/musculoskeletal pain, decreased appetite, rash and vomiting. The rate of all study drug discontinuation due to any adverse reaction was 1.9 % in patients treated with cetuximab in combination with encorafenib.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-07-15T11:55:00Z · SHA-256 073f5effd93351048ad74afee3f940b1c0ad5d24722452304a7b761a65e30f20 · Passage b928a17d1d514ec76b3d21dcd3cd062cde65731f7ccd53442e72c211c071ae20 · Zeichen 321–903 im Abschnitt